FDA Warns Sun Over Oxycodone Quality Control Issues

By Leigh Kamping-Carder

Law360, New York (September 01, 2010, 5:23 PM ET) -- The U.S. Food and Drug Administration has faulted a unit of Sun Pharma Global Inc. for lapses in quality control the regulator blames for “imploding” bottles of gemfibrozil, “sweating” nimodipine capsules and misplaced oxycodone pills.

The FDA said that Sun Pharmaceutical Industries Inc. had failed to address almost 20 consumer complaints and maintained insufficient quality controls at its Cranbury, N.J., manufacturing facility, according to an Aug. 25 letter made public Monday.

Multiple lots of packages of gemfibrozil, a lipid-reducing drug, imploded in the facility's sample room,...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles